Related Experiment Videos
[Idiopathic pulmonary fibrosis (IPF)]
1Fourth Department of Internal Medicine, Nippon Medical School.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 15, 2006
Summary
Interferon gamma (IFN-gamma) showed promise for idiopathic pulmonary fibrosis (IPF) in early studies. However, a large-scale trial found it did not improve progression-free survival or quality of life in progressive IPF cases.
Area of Science:
- Immunology
- Pulmonology
- Fibrosis Research
Context:
- Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with limited therapeutic options.
- Interferon gamma (IFN-gamma), a T-helper type 1 cytokine, has been investigated for its anti-fibrotic properties.
- Previous small-scale studies suggested potential benefits of IFN-gamma in IPF patients resistant to steroids.
Purpose:
- To evaluate the efficacy of interferon gamma-1b in improving progression-free survival, pulmonary function, and quality of life in IPF patients.
- To assess the lagged effect of respiratory function aggravation in IPF patients with mild to moderate disease deterioration.
- To build upon promising results from earlier small-scale clinical studies.
Summary:
- A large-scale Phase III clinical trial investigated interferon gamma-1b for IPF treatment.
- The study focused on patients with mild to moderate pulmonary function decline.
- Results indicated that interferon gamma-1b did not significantly affect progression-free survival, pulmonary function, or quality of life in progressive IPF cases.
Impact:
- The findings suggest that interferon gamma-1b may not be an effective treatment for all IPF patients, particularly those with progressive disease.
- This research contributes to understanding the limitations of cytokine-based therapies in managing IPF.
- Further research is needed to identify IPF patient subgroups who may benefit from specific therapeutic interventions.